Technology

Layered Approaches to Cancer Control

Next-Generation Precision Therapeutics

Kazia is advancing innovative therapeutic approaches designed to selectively reprogram the mechanisms that enable cancer to grow, adapt, and evade immune surveillance. By integrating epigenetic modulation, transcriptional regulation, and targeted protein degradation, we are developing therapies that address fundamental drivers of disease progression and treatment resistance.

This broader approach to cancer intervention has the potential to overcome the limitations of therapies directed at single mutations or isolated pathways, supporting more durable responses across heterogeneous and evolving tumors.

Building a Differentiated, Multi-Layered Oncology Platform

Our therapeutic strategy is focused on three complementary oncology platforms that converge on a common goal: therapeutically reprogramming cancer biology to overcome immune evasion, therapeutic resistance, and metastatic progression. By addressing the underlying mechanisms that drive tumor progression and treatment resistance, these approaches are designed to expand the reach of cancer therapies and enable more durable patient outcomes. Rather than pursuing a single platform, our approach is driven by clinically actionable mechanisms designed to overcome therapeutic resistance in aggressive and immunotherapy-refractory cancers.

Positioned at the Center of Oncology Innovation

Epigenetic Reprogramming

2025 Current Market
$19B+

Projected 2035
$92B+

Growth Driver
Oncology applications, demand for novel treatments, increased interest in precision medicine

Immune Reprogramming

Current Market
$83B+

Projected 2035
$409B+

Growth Driver
Increasing prevalence of cancer and need for innovative therapies, rising success of immunotherapies

Precision Pathway Reprogramming

Current Market
$137B+

Projected 2035
$300B+

Growth Driver
Increasing prevalence of cancer, advancements in targeted treatments

Epigenetic Reprogramming: Paxalisib & MSETC

Epigenetic dysregulation is increasingly recognized as a fundamental driver of immune evasion, therapeutic resistance, and cancer progression. Kazia's epigenetic reprogramming is designed to therapeutically reprogram chromatin-associated mechanisms that enable tumors to suppress immune responses and adapt to treatment.
Rather than directly targeting cancer cell proliferation alone, our technology seeks to restore transcriptional programs that support durable anti-tumor immunity and improve therapeutic responsiveness through selective modulation of disease-associated epigenetic regulators.


Featured Programs:

  • Paxalisib Reprograms epigenetic signaling through dual PI3K/mTOR inhibition, influencing downstream chromatin regulators associated with immune activation and therapeutic response
  • MSETC Selectively targets the disease-associated SETDB1 complex, restoring anti-tumor immune signaling through epigenetic reprogramming

Immune Reprogramming: Paxalisib, NDL2 & MSETC

Immune evasion is one of the defining hallmarks of cancer and a major driver of treatment resistance and disease progression. Kazia's immune reprogramming brings together complementary therapeutic approaches designed to restore effective anti-tumor immunity by targeting distinct biological mechanisms across the tumor microenvironment.

Unlike conventional immuno-oncology strategies that primarily focus on extracellular checkpoint blockade, our technology seeks to therapeutically reprogram immune function through precision pathway inhibition, nuclear protein degradation, and epigenetic modulation.


Featured Programs:

  • Paxalisib Reprograms the tumor microenvironment through dual PI3K/mTOR inhibition, enhancing anti-tumor immune responses while modulating mechanisms associated with immune evasion and therapeutic resistance
  • NDL2 Selectively targets tumor-associated PD-L1, addressing mechanisms of immune escape beyond the reach of conventional checkpoint inhibitors
  • MSETC Selectively targets the disease-associated SETDB1 complex, restoring anti-tumor immune signaling through epigenetic reprogramming

Precision Pathway Reprogramming: Paxalisib & EVT801

Precision pathway inhibition has transformed the treatment of many cancers by selectively targeting the molecular drivers of disease. Kazia's precision pathway reprogramming builds upon this foundation by leveraging precision pathway inhibition to influence the broader biological networks that drive immune evasion, therapeutic resistance, and metastatic progression.

Rather than simply blocking oncogenic signaling, our technology is designed to therapeutically reprogram cancer biology, creating the potential for deeper, more durable responses and enabling rational combination strategies across multiple tumor types.


Featured Programs:

  • Paxalisib Reprograms cancer biology through dual PI3K/mTOR pathway inhibition, restoring anti-tumor immunity and overcoming therapeutic resistance
  • EVT801 Reprograms the tumor microenvironment through VEGFR-3 inhibition, normalizing tumor vasculature, reducing immune suppression, and inhibiting metastatic progression

A Pipeline Advancing the Future of Cancer Treatment

We are advancing a diversified portfolio of development candidates spanning multiple therapeutic technologies, positioning us to deliver best- and first-in-class therapies across a broad spectrum of oncology indications.

View Our Pipeline